Nurix Therapeutics, Inc.
NRIX evidence brief
What we can confirm
- BioSniper Score:
- 5.6 / 10
- Market Cap:
- $2.71B
- Lead Asset:
- bexobrutideg (Phase 3)
What it means
What to watch
Prepared research question
What matters most for NRIX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NRIX
Nurix Therapeutics is a clinical-stage biotechnology company developing targeted protein degraders for oncology and inflammation indications, with its lead candidate bexobrutideg in pivotal-stage development for CLL.
Key risk: No product sales revenue
BioSniper Score
Based on 4 of 6 signals
Financial data as of Aug 31, 2026.
Tracking 2 pipeline candidates · 9 clinical trials for Nurix Therapeutics, Inc..
Nurix Therapeutics is a clinical-stage biotechnology company developing targeted protein degraders for oncology and inflammation indications, with its lead candidate bexobrutideg in pivotal-stage development for CLL.
- Lead candidate bexobrutideg (NX-5948) advanced into pivotal-stage development with the DAYBreak Phase 2 registrational program in relapsed/refractory CLL [sec · filed 2026-03-27].
- As of August 31, 2026, the company reported cash, cash equivalents and marketable securities of $1.1 billion [sec_mda · as of 2026-10-13].
- Collaboration revenue of $84.0 million was generated during fiscal 2025, with eligibility for up to $6.1 billion in potential future milestones and royalties across partnered programs [sec · filed 2026-03-27].
- The company does not have any products approved for sale and has not generated any revenue from product sales [sec_mda · as of 2026-10-13].
- Nurix leverages its proprietary DEL-AI platform to generate degraders and degrader antibody conjugates (DACs) as first-in-class or best-in-class drug candidates [sec_mda · as of 2026-10-13].
What works
- Strong cash position: $1.1 billion in cash, cash equivalents and marketable securities as of August 31, 2026, providing runway for clinical programs [sec_mda · as of 2026-10-13].
- Lead candidate bexobrutideg demonstrated an 83% objective response rate in Phase 1a/1b CLL trial with median progression-free survival of 22.1 months [sec · filed 2026-03-27].
- Significant non-dilutive collaboration revenue ($84.0 million in fiscal 2025) and potential for up to $6.1 billion in future milestones and royalties [sec · filed 2026-03-27].
- Differentiated platform (DEL-AI) and ligase expertise enabling development of first-in-class or best-in-class degraders across multiple protein classes [sec_mda · as of 2026-10-13].
What to weigh
- No approved products or product sales revenue; company is entirely dependent on equity offerings and collaborations for funding [sec_mda · as of 2026-10-13].
- Long-term capital requirements are uncertain and depend on clinical trial progress, costs, and potential additional collaborations [sec_mda · as of 2026-07-09].
- Cash position fluctuated significantly: $540.7M as of Feb 2026, $443.5M as of May 2026 (before expected $700M Roche payment), and $1.1B as of Aug 2026, indicating reliance on large one-time payments [sec_mda · as of 2026-04-08][sec_mda · as of 2026-07-09][sec_mda · as of 2026-10-13].
- Substantial additional financing will be needed to fund operations beyond the next 12 months [sec_mda · as of 2026-07-09].
From the filings
Quoted directly from source documents.
Bexobrutideg achieved 83% ORR in Phase 1a/1b CLL trial
“Presenting updated clinical data from the Phase 1a/1b clinical trial of bexobrutideg at the 2025 American Society of Hematology Annual Meeting demonstrating an 83% objective response rate, including complete responses, with a median progression-free survival of 22.1”
SEC filings · March 27, 2026
Cash position as of August 31, 2026
“As of August 31, 2026, we had $1.1 billion in cash, cash equivalents and marketable securities.”
SEC MD&A · October 13, 2026
No product sales revenue
“We do not have any products approved for sale, and we have not generated any revenue from product sales.”
SEC MD&A · October 13, 2026
Collaboration revenue and milestone potential
“Generating $84.0 million in collaboration revenue during fiscal 2025 and maintaining eligibility for up to $6.1 billion in potential future milestones and royalties across our partnered programs.”
SEC filings · March 27, 2026
Catalyst timeline
- 2021-05-05 · Phase1_Start: NX-2127 BTK degrader study — Initiation of Phase 1 dose escalation study for NX-2127 in relapsed/refractory B-cell malignancies.
- 2021-09-29 · Phase1_Start: NX-1607 CBL-B inhibitor study — Initiation of Phase 1a dose escalation study for NX-1607 in advanced malignancies.
- 2022-04-13 · Phase1_Start: NX-5948 (bexobrutideg) study — Initiation of Phase 1 dose escalation and cohort expansion study for NX-5948 in relapsed/refractory B-cell malignancies.
- 2024-08-20 · Phase1_Start: Placebo-controlled study — Initiation of Phase 1, 2-part, placebo-controlled, double-blinded study for an undisclosed candidate.
Risks & what to watch (4)›
Key risks
- No product sales revenue — Company has no approved products and no revenue from product sales; entirely dependent on equity and collaborations [sec_mda · as of 2026-10-13].
- Cash runway limited to ~12 months — Existing cash sufficient for at least 12 months; substantial additional financing needed beyond that [sec_mda · as of 2026-07-09].
- Clinical trial execution risk — Pivotal trials for bexobrutideg and other programs may be delayed, added, or terminated, affecting costs and timelines [sec_mda · as of 2026-07-09].
- Dependence on partnership milestones — Future funding relies on milestones and royalties from partners; any partner program changes could impact cash flow [sec · filed 2026-03-27].
What to watch
- Execution of DAYBreak-201 and DAYBreak-306 registrational studies for bexobrutideg in CLL [sec · filed 2026-03-27].
- Completion of new tablet formulation SAD/MAD study and IND filing for bexobrutideg in an I&I indication [sec · filed 2026-03-27].
- Advancement of Sanofi's STAT6 degrader program through IND-enabling studies [sec · filed 2026-03-27].
- Receipt of $700 million upfront payment from Roche expected in third fiscal quarter of 2026 [sec_mda · as of 2026-07-09].
Sources: Catalysts · SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Nurix Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Nurix Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.23 · 4% dilution
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
0 buys · 20 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
196
Total value held
$1.75B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 8,925,642 | $138.3M |
| redmile group, llc | 7,732,808 | $119.9M |
| vestal point capital, lp | 6,500,000 | $100.8M |
| deep track capital, lp | 6,345,244 | $98.4M |
| fmr llc | 5,541,271 | $85.9M |
| state street corp | 5,141,195 | $79.7M |
| morgan stanley | 4,931,999 | $76.4M |
| baker bros. advisors lp | 4,658,556 | $72.2M |
| vanguard capital management llc | 4,427,112 | $68.6M |
| general atlantic, l.p. | 4,101,865 | $63.6M |
Showing top 10 of 196 institutional holders of Nurix Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 18.8%
- Days to cover
- 12.9
- Shares short
- 19,201,724
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NRIX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Nurix Therapeutics, Inc.?
Nurix Therapeutics is a clinical-stage biotechnology company developing targeted protein degraders for oncology and inflammation indications, with its lead candidate bexobrutideg in pivotal-stage development for CLL.
What is Nurix Therapeutics, Inc.'s lead drug candidate?
Nurix Therapeutics, Inc.'s most advanced tracked candidate is bexobrutideg (Phase 3) for Treatment of relapsed or refractory B-cell malignancies; being explored for autoimmune and inflammatory diseases. Phase 2 study in patients with relapsed or refractory CLL who failed three previous lines of therapy. Fast Track designation in CLL/SLL and WM..
Who is the CEO of Nurix Therapeutics, Inc.?
Dr. Arthur T. Sands M.D., Ph.D. is the chief executive officer of Nurix Therapeutics, Inc. (NRIX).
Where is Nurix Therapeutics, Inc. headquartered?
Nurix Therapeutics, Inc. (NRIX) is headquartered in Brisbane, CA, United States.
What therapeutic areas does Nurix Therapeutics, Inc. focus on?
Nurix Therapeutics, Inc. develops therapies across Oncology, Immunology, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.